Maternal & Child Health Research Institute (MCHRI)


Showing 711-720 of 1,005 Results

  • Judith Prochaska

    Judith Prochaska

    Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)

    Current Research and Scholarly InterestsDr. Prochaska's clinical trials research focuses on developing and testing evidence-based interventions for tobacco, other substance use, physical activity, and diet. She has led randomized controlled trials of treatments that combine motivational, behavioral, and pharmacologic strategies, including use of telemedicine, therapeutic relational agents, social-media–supported interventions, and tailored programs for socio-demographically diverse and at-risk groups to advance population health.

  • Jochen Profit

    Jochen Profit

    Wendy J. Tomlin-Hess Endowed Professor

    Current Research and Scholarly InterestsFunded by NIH R01 grants:

    1) Development and application of composite measure of NICU quality - Baby-MONITOR

    2) High reliability, safety culture and caregiver resilience as modifiers of care quality

    3) Modifiable racial/ethnic disparities in quality of care delivery

    4) Effectiveness of regionalized care delivery systems for preterm newborns

  • Stephanie Pun, MD

    Stephanie Pun, MD

    Clinical Associate Professor, Orthopaedic Surgery

    Current Research and Scholarly InterestsDr. Pun specializes in the treatment of complex hip disorders with surgical hip preservation options for children, adolescents, and adults. Her goal is to enhance hip function in active individuals and to prevent the early development of hip osteoarthritis.

  • Stanley Qi

    Stanley Qi

    Associate Professor of Bioengineering and, by courtesy, of Biomedical Data Science

    BioStanley Qi (publishing as Lei S. Qi) is a pioneer in the field of genome engineering and the architect of the foundational technologies that transitioned CRISPR from a "cutting" tool into a universal platform for Programmable Biology. As the inventor of CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), Qi established the first methods for the precise, reversible, and targeted regulation of the human genome without altering the DNA sequence.

    The Qi Lab integrates scalable genomic perturbation with live-cell and super-resolution imaging and computation-guided design to redefine the boundaries of cellular control. Under Dr. Qi’s leadership, the group has fundamentally expanded the genome engineering toolbox, evolving CRISPR from a single editing tool into a multidimensional platform for the precise control of dynamic and spatial cell states. This work includes establishing foundational technologies and architectures for precise epigenetic editing, multiplexed regulation of the transcriptome, programmable 3D genome organization, and spatial control of RNA logistics. By pioneering real-time visualization of chromatin dynamics and RNA in living cells, the lab provides an unprecedented window into the fundamental "control principles of life."

    This principle-driven technology lineage has moved into the clinic, with the lab's compact epigenetic editor currently in first-in-human clinical testing for FSHD muscular dystrophy (NCT06907875). This milestone represents a core mission of the lab: translating foundational engineering into next-generation therapeutics that act predictably as dynamic, complex systems.

    Beyond single-cell control, the Qi Lab is building a framework for synthetic cell–cell communication, with a particular emphasis on the bidirectional interplay between immune cells and neurons. The lab’s goal is to move beyond describing molecular parts to discovering fundamental control principles in living systems: how regulatory landscapes create stable states and memory, how spatial genome–RNA organization shapes dynamic responses, and how engineered cell–cell interactions can generate emergent multicellular behaviors.

    By integrating computational design with experimental biology, Dr. Qi aims to identify the generalizable rules linking molecular programs to systems-level physiology. He is a Chan Zuckerberg Biohub Investigator and an Institute Scholar at the Sarafan ChEM-H, and is dedicated to shaping the technical and ethical frameworks that will define the future of human genome engineering.

  • Xiaojie Qiu

    Xiaojie Qiu

    Assistant Professor of Genetics and, by courtesy, of Computer Science

    Current Research and Scholarly InterestsAt the Qiu Lab, our mission is to unravel and predict the intricacies of gene regulatory networks and cell-cell interactions pivotal in mammalian cell fate transitions over time and space, with a special emphasis on heart evolution, development, and disease. We are a dynamic and interdisciplinary team, harnessing the latest advancements in machine learning as well as single-cell and spatial genomics by integrating the predictive power of systems biology with the scalability of machine learning,

  • Thomas Quertermous, MD

    Thomas Quertermous, MD

    William G. Irwin Professor of Cardiovascular Medicine

    Current Research and Scholarly InterestsUnderstanding genetic basis of cardiovascular function and disease.